0001209191-22-025537.txt : 20220425
0001209191-22-025537.hdr.sgml : 20220425
20220425171304
ACCESSION NUMBER: 0001209191-22-025537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220421
FILED AS OF DATE: 20220425
DATE AS OF CHANGE: 20220425
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walker Neal
CENTRAL INDEX KEY: 0001604457
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 22850592
MAIL ADDRESS:
STREET 1: 15 NEW ENGLAND EXECUTIVE PARK
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-21
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001604457
Walker Neal
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
1
1
0
0
President and CEO
Common Stock
2022-04-21
4
S
0
25000
15.2379
D
1290763
D
Common Stock
2022-04-22
4
S
0
25000
15.0439
D
1265763
D
Common Stock
2022-04-25
4
S
0
20000
15.1828
D
1245763
D
These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Mark Ballantyne, Attorney-in-Fact
2022-04-25